PATENT COOPERATION TREATY

PCT

REC'D	1	1	JUL	2005
WIPO				PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 433 WO	RTHER ACTION See Form PCT/IPEA/416						
International application No. Internation	al filing date (day/month/year) Priority date (day/month/year)						
PCT/DK2004/000243 02.04.20	04.04.2003						
International Patent Classification (IPC) or national classi	fication and IPC						
C07D211/70, C07D405/12, A61K31/4409, A6-	IP25/00						
Applicant							
H. LUNDBECK A/S et al.							
Authority under Article 35 and transmitted to	- · · · · · · · · · · · · · · · · · · ·						
2. This REPORT consists of a total of sheets,	including this cover sheet.						
3. This report is also accompanied by ANNEXE	S, comprising:						
1	ational Bureau) a total of sheets, as follows:						
□ sheets of the description, claims and/or sheets containing rectifica Administrative Instructions).	and/or drawings which have been amended and are the basis of this report tions authorized by this Authority (see Rule 70.16 and Section 607 of the						
sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the							
Supplemental Box. b. Sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)) , containing a						
sequence listing and/or tables related	thereto, in computer readable form only, as indicated in the Supplemental e Section 802 of the Administrative Instructions).						
A This report contains indications valeting to the	o following the man						
4. This report contains indications relating to th	e following items:						
☐ Box No. I Basis of the opinion							
Box No. II Priority							
·	ent of opinion with regard to novelty, inventive step and industrial applicability						
Box No. IV Lack of unity of invention	vention						
☑ Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement							
☐ Box No. VI Certain documents cited	- Plantanor Cappelling Capit Clarenterin						
☐ Box No. VII Certain defects in the inter	onal application						
<u> </u>	the international application						
Date of submission of the demand	Date of completion of this report						
24.09.2004	08.07.2005						
Name and malling address of the international	Authorized Officer						
preliminary examining authority:	Authorized Officer						
European Patent Office - P.B. 5818 Pater NL-2280 HV Rijswijk - Pays Bas	ntlaan 2 Diederen, J						
Tel. +31 70 340 - 2040 Tx: 31 651 epo nl							
Fax: +31 70 340 - 3016	Telephone No. +31 70 340- 1097						

International application No. PCT/DK2004/000243

	Box	No. I Basis of the report				
1.	With regard to the language , this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.					
	 □ This report is based on translations from the original language into the following language, which is the language of a translation furnished for the purposes of: □ international search (under Rules 12.3 and 23.1(b)) □ publication of the international application (under Rule 12.4) □ international preliminary examination (under Rules 55.2 and/or 55.3) 					
2. With regard to the elements* of the international application, this report is based on <i>(replacement sheets w have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in the report as "originally filed" and are not annexed to this report):</i>						
	Des	cription, Pages				
	1-46	as originally filed				
Claims, Numbers						
	1-17	as originally filed				
		a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing				
3.		The amendments have resulted in the cancellation of: the description, pages the claims, Nos. the drawings, sheets/figs the sequence listing (specify): any table(s) related to sequence listing (specify):				
4.	hac Sup	This report has been established as if (some of) the amendments annexed to this report and listed below into been made, since they have been considered to go beyond the disclosure as filed, as indicated in the oplemental Box (Rule 70.2(c)). the description, pages the claims, Nos. the drawings, sheets/figs the sequence listing (specify): any table(s) related to sequence listing (specify):				
	*	If item 4 applies some or all of these sheets may be marked "superseded "				

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/DK2004/000243

		c No. III Non-establishment c licability	of opi	nion with regard to novelty, inventive step and industrial		
1.	The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:					
		the entire international application,				
	\boxtimes	claims Nos. 16				
		because:				
	Ø	the said international application, or the said claims Nos. 16 relate to the following subject matter which does not require an international preliminary examination (specify):				
	•	see separate sheet				
		the description, claims or drawings <i>(indicate particular elements below)</i> or said claims Nos. are so unclear that no meaningful opinion could be formed <i>(specify)</i> :				
		the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.				
		no international search report has been established for the said claims Nos.				
		the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:				
		the written form		has not been furnished		
				does not comply with the standard		
		the computer readable form		has not been furnished		
				does not comply with the standard		
		the tables related to the nucleonot comply with the technical re	tide (equir	and/or amino acid sequence listing, if in computer readable form only, do ements provided for in Annex C-bis of the Administrative Instructions.		
	П	See senarate sheet for further	detai	ie		

International application No. PCT/DK2004/000243

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

1-17

No: Claims

Inventive step (IS)

Yes: Claims

1-17

No: Claims

Industrial applicability (IA)

Yes: Claims

1-15,17

No: Claims

2. Citations and explanations (Rule 70.7):

see separate sheet

Box No. VI Certain documents cited

 Certain published documents (Rule 70.10) and /or

2. Non-written disclosures (Rule 70.9)

see separate sheet

Reference is made to the following document:

D1: WO 01/49678 A (KROG JENSEN CHRISTIAN; ROTTLAENDER MARIO (DK); ANDERSEN KIM (DK); MIK) 12 July 2001 (2001-07-12)

Re Item III

Ä

1

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Claim 16 relates to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(l) PCT).

Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

The application fulfills the requirements of Article 33(2) and 33(3) PCT with respect to Novelty and Inventive Step.

The subject-matter of the present application is novel over D1 as the compounds of D1 are substituted at the nitrogen atom of the nitrogen containing heterocycle, whereas the compounds of the present application are unsubstituted at this position.

Document D1 is considered to be the closest prior art. This document discloses compounds of formula (I) which are used as 5-HT1A receptor agonists.

The difference of these compounds with the compounds of the present application is that the nitrogen atom of the nitrogen containing ring is substituted in D1 whereas in the present application it is not. In D1 the nitrogen containing heterocycle can be either piperazines, piperidines or dihydropyridines in the first claim. There is no subclaim where only the dihydropyridine is claimed. The examples all comprise piperazines.

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)

International application No.

PCT/DK2004/000243

The problem to be solved by the applicant was to provide alternative compounds for use as SSRI's. A skilled person would not come to the solution proposed in the present application starting from D1 as he would have to leave out the substituent on the nitrogen atom and to choose from a list of three possible nitrogen containing heterocycles of which the dihydropyridine is actually not at all exemplified in D1.

The subject-matter of the present application is therefore considered to involve an inventive step over D1.